A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral
interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of
relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability,
and anti-tumor activity of CPI-818 as a single drug.